D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (MEFOX)

• ClinicalTrials.gov Identifier: NCT05212012
• Recruitment Status: Recruiting
• First Posted: January 27, 2022
• Last Update Posted: April 28, 2022
• Sponsor: AIO-Studien-gGmbH
• Collaborator: Deutsche Krebshilfe e.V., Bonn (Germany)
• Information provided by (Responsible Party): AIO-Studien-gGmbH

Tracking Information

• First Submitted Date: November 2, 2021
• First Posted Date: January 27, 2022
• Last Update Posted Date: April 28, 2022
• Actual Study Start Date: February 17, 2022
• Estimated Primary Completion Date: June 15, 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 23, 2022)

• Evaluation of the recommended dose for phase-II-trial [ Time Frame: 18 months ]
  Evaluation of the toxicity-profile of D,L-methadone and the dose-limiting toxicity (DLT) in combination with mFOLFOX6
• Disease control rate 12 weeks after randomization (ITT-population) [ Time Frame: 12 weeks after randomization ]
  Evaluation of the disease control rate of D,L-methadone plus mFOLFOX6 compared to mFOLFOX6 alone in the treatment of patients with advanced colorectal cancer. The disease control rate is defined as response (CR or PR) or stabilization (SD) of the tumor disease at 12 weeks after randomization (DCR) according to RECIST1.1.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: January 23, 2022)

• Disease control rate (DCR) 12 weeks after randomization (per-protocol-population) [ Time Frame: 12 weeks ]
  The disease control rate is defined as response (CR or PR) or stabilization (SD) of the tumor disease at 12 weeks after randomization (DCR) according to RECIST1.1
• Overall response rate [ Time Frame: 46 months ]
  All tumor evaluation is performed according to RECIST 1.1
• patient diary [ Time Frame: 46 months ]
  Collection compliance with a diary
• Progression-free survival [ Time Frame: after 46 months ]
  Progression-free survival (PFS) will be defined as the time from randomization to the time of progress (according to RECIST 1.1) or death, or to the date of last tumor assessment without any such event (censored observation)
• Overall survival [ Time Frame: 46 months ]
  The duration of overall survival (OS) will be determined by measuring the time interval from randomization to the date of death or last observation (censored)
• Quality of life assessment [ Time Frame: 46 months ]
  EORTC QLQ-C30 ("European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30)" ). The EORTC QLQ-C30 is composed of a global health status/QoL-score, five function scales, three symptom scales and five single items (dyspnea, insomnia, appetite loss, constipation, diarrhea). Each item has four response alternatives: (1) "not at all", (2) "a little", (3) "quite a bit", and (4) "very much" - except the two items of the global health-status/quality of life scale which have response options ranging from (1) "very poor" to (7) "excellent".
• Adverse events [ Time Frame: 46 months ]
  Evaluation of the safety- and tolerability profile

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer
• Official Title: A Phase I/II Trial of D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer - The AIO-MEFOX Trial (AIO-KRK-0119)

Brief Summary

This is a phase I/II-trial with D,L-methadone and mFOLFOX6 in the treatment of patients with histologically confirmed chemo-refractory colorectal carcinoma.

The aim of the phase-I trial is to evaluate the toxicity-profile and the dose-limiting toxicity of D,L-methadone combined with mFOLFOX6. Furthermore, to estimate the maximum tolerated dose and the recommended dose for phase-II-trial in the treatment of patients with histologically confirmed colorectal carcinoma not amenable to or progressing while having received all standard therapies.

The primary endpoint of the randomized phase-II study is to determine the disease control rate 12 weeks after randomization of patients with histologically confirmed advanced colorectal carcinoma upon treatment with D,L methadone plus mFOLFOX6 versus mFOLFOX6 alone. Overall response rate according to RECIST1.1, progression free survival (PFS), overall survival (OS), quality of life (QoL) according to the EORTC QLQc30 questionnaire, patient-reported outcomes and safety will be evaluated as secondary objectives.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2

Study Design

Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Phase I: 3+3 dose escalation study (non-randomized) - max. 18 participant

after Phase I start with a Amendment Phase II: Open-label, 2:1 randomized, controlled trial - 64 participant Patients in the mFOLFOX6 alone arm are allowed to cross over and receive methadone hydrochloride in combination with mFOLFOX6 upon disease progress

Masking: None (Open Label)
Primary Purpose: Treatment

• Condition: Chemo-refractory Colorectal Carcinoma

Intervention

Drug: Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)

Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)

Study Arms

Experimental: D,L-methadonehydrochloride + mFOLFOX6

Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)

Treatment with mFOLFOX6 every two weeks; will be administered:

Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1) LV at a dose of 400 mg/m² iv over two hours (day 1) 5-FU at a dose of 2400 mg/m² iv over 46 hours (day 1-3)

Intervention: Drug: Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: January 23, 2022): 18
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: June 15, 2025
• Estimated Primary Completion Date: June 15, 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Advanced, histologically confirmed, metastatic colorectal carcinoma not suitable for resection and chemorefractory or Previously employed chemotherapy regimens and agents should comprise the following: Fluoropyrimidines, oxaliplatin, irinotecan, antiangiogenic agents (bevacizumab, aflibercept or ramucirumab), anti-EFGR-mAbs (in case of all-Ras-wildtype and left-sided primary tumor) and Trifluridin/Tipiracil (TAS102)
• Microsatellite stable subset (MSS) of colorectal cancer
• Prior antineoplastic therapy or radiochemotherapy is allowed up to two weeks prior to start of the study medication. However, for the phase II part of the trial, failure of this strategy must be confirmed. In case of prior radiotherapy/radiochemotherapy the target lesion used for tumor evaluation must not be in the radiation field.
• There must be an oxaliplatin free period of at least 6 months prior to start of the study medication.
• No polyneuropathy of > grade 1
• Tumor-related ECOG performance status 0-2
• Anticipated life expectancy ≥ 12 weeks
• Creatinine clearance ≥ 30 ml/min
• Serum total bilirubin level ≤ 3 x ULN.
• ALT and AST ≤ 2.5 x ULN or ≤ 5.0 x ULN in the presence of liver metastasis (established after adequate biliary drainage)
• White blood cell count ≥ 3.5 x 106/ml, neutrophil granulocytes count ≥ 1,5 x 106/ml, platelet count ≥ 100 x 106/ml
• Pain that has to be controllable without concomitant use of opioids
• Signed informed consent according to ICH/GCP and national/local regulations (participation in translational research is obligate)
• None of the following concomitant medications: MAO-B-Inhibitors, strong inductors or inhibitors of CYP3A4, antiarrhythmic drugs of class I and III or other drugs that have potential for QT-prolongation
• Age ≥ 18 years
• At least one measurable target lesion according to RECIST 1.1. Pre-irradiated or locally treated lesions must not be used as target lesions.

Exclusion Criteria:

• Microsatellite unstable CRC (MSIhigh)
• Chronic infectious diseases, immune deficiency syndromes
• Polyneuropathy >grade I according to CTCAE V4.03
• Premalignant hematologic disorders, e.g. myelodysplastic syndrome
• Disability to understand and sign written informed consent document

• Past or current history of malignancies except for the indication under this study and curatively treated:

  • Basal and squamous cell carcinoma of the skin
  • In-situ carcinoma of the cervix
  • Other malignant disease without recurrence after at least 3 years of follow-up
• Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment
• History of or evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumor, seizure not controlled with standard medical therapy or history of stroke).
• Severe non-healing wounds, ulcers or bone fractions
• Evidence of bleeding diathesis or coagulopathy
• Patients not receiving therapeutic anticoagulation must have an INR ≤ 1.4 or PTT ≤ 40 sec within 28 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution)
• Major surgical procedures or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study.
• Pregnancy or breastfeeding women.
• Use of cannabinoids because of overlapping and /or potentiating of potential side effects
• Concomitant daily use of opioids in the last 3 months including methadone prior start of study medication
• Subjects with known allergies to the study drugs or to any of its excipients.
• Treatment with another investigational drug or participation in another interventional trial (within the 14 days prior randomization or 5 plasma half-lifes of the used investigational drug, whatever is longer)
• Congenital QT-syndrome.
• Alcohol abuse.
• Bronchial asthma.
• Liver cirrhosis > Child-Pugh classification A.
• Any psychological, familial, sociological or geographical condition potentially compromising compliance with the study protocol and the follow-up schedule; those conditions should be discussed with the patient prior to registration in the trial

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: AIO-Studien-gGmbH; +49308145344 ext 70; info@aio-studien-ggmbh.de

• Listed Location Countries: Germany

Administrative Information

• NCT Number: NCT05212012
• Other Study ID Numbers: AIO-KRK-0119; 2019-004158-26 ( EudraCT Number )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: AIO-Studien-gGmbH
• Original Responsible Party: Same as current
• Current Study Sponsor: AIO-Studien-gGmbH
• Original Study Sponsor: Same as current
• Collaborators: Deutsche Krebshilfe e.V., Bonn (Germany)

Investigators

• Principal Investigator: Thomas Seufferlein, Prof.Dr.med.; Ulm University Hospital, Department of Internal Medicine I

• PRS Account: AIO-Studien-gGmbH
• Verification Date: April 2022